How a new fungal genome-editing tool could open fresh paths to cancer treatments

Researchers have spent decades—and billions of dollars—sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they're ruining ...

Akari Therapeutics Plc: Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 ...

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

Detailed price information for Akari Therapeutics ADR (AKTX-Q) from The Globe and Mail including charting and trades.
IEEE

Membrane InGaAlAs Electro-Absorption Modulator Integrated with III-V/Si DFB Laser with 150-Gbaud Modulation on Si Photonics Platform

Abstract: We fabricate an O-band membrane InGaAlAs electro-absorption modulator (EAM) integrated with a III-V/Si DFB laser on a Si photonics platform. The device exhibits 6-mW fibre-coupled output ...